Eledon Pharmaceuticals In... (ELDN)
4.14
0.06 (1.47%)
At close: Feb 28, 2025, 3:59 PM
4.00
-3.50%
After-hours: Feb 28, 2025, 07:59 PM EST
No 1D chart data available
| Bid | 3.94 |
| Market Cap | 247.62M |
| Revenue (ttm) | 644.02K |
| Net Income (ttm) | 13.96M |
| EPS (ttm) | 0.73 |
| PE Ratio (ttm) | 5.68 |
| Forward PE | -4.62 |
| Analyst | Buy |
| Ask | 4.34 |
| Volume | 134,764 |
| Avg. Volume (20D) | 389,825 |
| Open | 4.07 |
| Previous Close | 4.08 |
| Day's Range | 3.98 - 4.18 |
| 52-Week Range | 1.52 - 5.54 |
| Beta | 0.79 |
About ELDN
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical tri...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2014
Employees 20
Stock Exchange NASDAQ
Ticker Symbol ELDN
Website https://eledon.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ELDN stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 286.01% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago
-11.41%
Eledon Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
10 months ago
-7.38%
Eledon Pharmaceuticals shares are trading lower after the company announced an $50 million oversubscribed private placement. The company announced clinical progress with tegoprubart in the prevention of transplant rejection.
